Reply to: Comments on “Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer”

Sarah M. H. Einerhand; Nick van Dijk; Michiel S. van der Heijden; Bas W. G. van Rhijn

doi:https://doi.org/10.1002/ijc.34207

Reply to: Comments on “Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer”

Sarah M. H. Einerhand, Nick van Dijk, Michiel S. van der Heijden, Bas W. G. van Rhijn

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	1849-1850
Number of pages	2
Journal	International Journal of Cancer
Volume	151
Issue number	10
Early online date	2022
DOIs	https://doi.org/10.1002/ijc.34207
Publication status	Published - 15 Nov 2022

Access to Document

https://doi.org/10.1002/ijc.34207

Cite this

@article{66cd80be1cc34fd098a4ade7e0f42ef9,

title = "Reply to: Comments on “Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer”",

author = "Einerhand, {Sarah M. H.} and {van Dijk}, Nick and {van der Heijden}, {Michiel S.} and {van Rhijn}, {Bas W. G.}",

note = "Funding Information: Michiel S. van der Heijden has received research support from Bristol‐Myers Squibb, AstraZeneca, 4SC and Roche and consultancy fees from Bristol‐Myers Squibb, Merck, Merck Sharp & Dohme, Roche, AstraZeneca, Seattle Genetics, Pfizer and Janssen (all paid to the Netherlands Cancer Institute). Bas W. G. van Rhijn took part in Advisory Board meetings of QED Therapeutics and Ferring. No other authors have disclosures relevant to this work.",

year = "2022",

month = nov,

day = "15",

doi = "https://doi.org/10.1002/ijc.34207",

language = "English",

volume = "151",

pages = "1849--1850",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Reply to: Comments on “Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer”. / Einerhand, Sarah M. H.; van Dijk, Nick; van der Heijden, Michiel S. et al.
In: International Journal of Cancer, Vol. 151, No. 10, 15.11.2022, p. 1849-1850.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Reply to

T2 - Comments on “Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer”

AU - Einerhand, Sarah M. H.

AU - van Dijk, Nick

AU - van der Heijden, Michiel S.

AU - van Rhijn, Bas W. G.

N1 - Funding Information: Michiel S. van der Heijden has received research support from Bristol‐Myers Squibb, AstraZeneca, 4SC and Roche and consultancy fees from Bristol‐Myers Squibb, Merck, Merck Sharp & Dohme, Roche, AstraZeneca, Seattle Genetics, Pfizer and Janssen (all paid to the Netherlands Cancer Institute). Bas W. G. van Rhijn took part in Advisory Board meetings of QED Therapeutics and Ferring. No other authors have disclosures relevant to this work.

PY - 2022/11/15

Y1 - 2022/11/15

UR - http://www.scopus.com/inward/record.url?scp=85135602687&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/ijc.34207

DO - https://doi.org/10.1002/ijc.34207

M3 - Comment/Letter to the editor

C2 - 35815942

SN - 0020-7136

VL - 151

SP - 1849

EP - 1850

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 10

ER -

Reply to: Comments on “Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer”

Access to Document

Other files and links

Cite this